Amato Davide, Stasi Maria Antonietta, Borsini Franco, Nencini Paolo
Department of Human Physiology and Pharmacology "Vittorio Erspamer", University of Rome "La Sapienza", Piazzale Aldo Moro 5, 00185, Rome, Italy.
Psychopharmacology (Berl). 2008 Oct;200(2):157-65. doi: 10.1007/s00213-008-1229-1. Epub 2008 Jul 3.
Polydipsia is a severe complication of long-term schizophrenia and, despite its unknown pathogenesis, is empirically treated with typical or atypical antipsychotics. In the rat, nonregulatory water intake is induced by repeated administration of amphetamine-like compounds or by the D2/3 agonist, quinpirole.
This study is aimed at determining the potential activity of antipsychotic compounds with different affinities for D2 receptors in preventing and/or reversing quinpirole-induced polydipsia.
Male Sprague-Dawley rats were treated with five injections of quinpirole (0.5 mg/kg i.p.) to induce polydipsia. The oral effects of haloperidol, olanzapine, clozapine, and ST2472 on QNP-induced polydipsia were analyzed in the following two schedules. In the preventive schedule, haloperidol (0.2, 0.4, and 0.8 mg/kg), olanzapine (1.5, 3, and 6 mg/kg), ST2472 (1 and 2 mg/kg), and clomipramine (5, 10, and 20 mg/kg) were given in combination with quinpirole from day 1 to day 5. In the reversal schedule, rats showing quinpirole-induced polydipsia on the third day received haloperidol (0.4 mg/kg), olanzapine (1.5 and 3 mg/kg), clozapine (10, 20, and 40 mg/kg), ST2472 (1, 2, 5, and 10 mg/kg), and clomipramine (5, 10, and 20 mg/kg) before quinpirole on days 4 and 5.
Haloperidol both prevented and reversed quinpirole-induced polydipsia, whereas olanzapine and ST2472 only reversed it. Clomipramine prevented but did not reverse quinpirole-induced polydipsia, and clozapine did not reverse it either.
We suggest that, once developed, polydipsia is governed by dopaminergic D2 mechanisms. In contrast, either an increase in the serotoninergic tone or an inhibition of D2 receptors can modulate the development of quinpirole-induced excessive drinking.
烦渴是长期精神分裂症的一种严重并发症,尽管其发病机制尚不清楚,但通常使用典型或非典型抗精神病药物进行经验性治疗。在大鼠中,反复给予苯丙胺样化合物或D2/3激动剂喹吡罗可诱导非调节性饮水。
本研究旨在确定对D2受体具有不同亲和力的抗精神病化合物在预防和/或逆转喹吡罗诱导的烦渴方面的潜在活性。
雄性Sprague-Dawley大鼠接受五次喹吡罗注射(0.5mg/kg,腹腔注射)以诱导烦渴。在以下两种方案中分析氟哌啶醇、奥氮平、氯氮平和ST2472对喹吡罗诱导的烦渴的口服作用。在预防方案中,从第1天到第5天,氟哌啶醇(0.2、0.4和0.8mg/kg)、奥氮平(1.5、3和6mg/kg)、ST2472(1和2mg/kg)和氯米帕明(5、10和20mg/kg)与喹吡罗联合给药。在逆转方案中,在第3天出现喹吡罗诱导的烦渴的大鼠在第4天和第5天在喹吡罗给药前接受氟哌啶醇(0.4mg/kg)、奥氮平(1.5和3mg/kg)、氯氮平(10、20和40mg/kg)、ST2472(1、2、5和10mg/kg)和氯米帕明(5、10和20mg/kg)。
氟哌啶醇既能预防又能逆转喹吡罗诱导的烦渴,而奥氮平和ST2472只能逆转它。氯米帕明能预防但不能逆转喹吡罗诱导的烦渴,氯氮平也不能逆转它。
我们认为,一旦出现烦渴,其受多巴胺能D2机制支配。相比之下,5-羟色胺能张力的增加或D2受体的抑制均可调节喹吡罗诱导的过度饮水的发展。